爵士製藥 JAZZ 深 滬
交易中 08-21 11:20:04 美东时间
119.185
+0.115
+0.10%
華盛通- 最 高119.85
- 今 開118.20
- 成交量 15.31万股
- 最 低 118.20
- 昨 收 119.07
- 總市值 72.12亿
- 52周最高 148.0568
- 市盈率 靜 13.78
- 換手率 0.25%
- 52周最低 95.49
- 委 比 92.42%
- 總股本 6051.10万
- 歷史最高 194.73
- 量 比 0.98
- 振 幅 1.39%
- 歷史最低 31.87
- 每 手 1
- 風險率 10.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an over...
今天 04:15
Beyond The Numbers: 5 Analysts Discuss Jazz Pharmaceuticals Stock
Across the recent three months, 5 analysts have shared their insights on Jazz P...
08-20 22:01
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $202 price target.
08-20 21:09
Jazz Pharmaceuticals enters exclusive licensing deal with Saniona
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Saniona on Wednesday announced a global license agreement between the two companies. Under the deal, Jazz (NASDAQ:JAZZ) will obtain exclusive worldwide rights to...
08-20 20:23
Jazz Pharmaceuticals Strikes $1B-Plus Deal With Saniona To Develop Promising New Epilepsy Drug
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Saniona (Nasdaq OMX: SANION) today announce that the companies have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a
08-20 19:34
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
FDA Grants Accelerated Approval To Dordaviprone For Diffuse Midline Glioma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma
08-07 02:28
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $162
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target from $165 to $162.
08-07 00:22
Jazz Pharmaceuticals Raises FY2025 GAAP EPS Guidance from $(10.00)-$(7.50) to $(9.25)-$(7.50) vs $(9.15) Est
Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2025 GAAP EPS guidance from $(10.00)-$(7.50) to $(9.25)-$(7.50) vs $(9.15) analyst estimate..
08-06 04:09
Jazz Pharmaceuticals Lowers FY2025 Adj EPS Guidance from $20.50-$22.10 to $4.80-$5.60 vs $4.94 Est; Narrows FY2025 Sales Guidance from $4.150B-$4.400B to $4.150B-$4.300B vs $4.231B Est
Jazz Pharmaceuticals (NASDAQ:JAZZ) lowers FY2025 Adj EPS guidance from $20.50-$22.10 to $4.80-$5.60 vs $4.94 analyst estimate. Narrows FY2025 sales outlook from $4.150 billion-$4.400 billion to $4.150 billion-$4.300
08-06 04:09
